AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05034952
Drug: HB/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT05034952
Drug: Placebo (matched to VX-548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-548 for oral administration.
Trial: NCT05034952
Drug: Placebo (matched to HB/APAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to HB/APAP for oral administration.
Trial: NCT05351437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT05122702
Drug: modified Shenling Baizhu San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified Shenling Baizhu San granules, twice daily for 12 weeks.
Trial: NCT05553938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin matched placebo tablet
Trial: NCT05468073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
Trial: NCT05948865
Drug: CPO301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous injection
Trial: NCT06222879
Drug: HRS-8080; SHR-A2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive HRS-8080 and SHR-A2009
Trial: NCT06222879
Drug: SHR-A2009; SHR-1316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SHR-A2009 and SHR-1316
Trial: NCT04977180
Drug: Cardioprotection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
Trial: NCT05279703
Drug: Epinephrine 0.03
RxNorm normalized name: epinephrine 0.032 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine infusion rate of 0.03 mcg/kg/min
Trial: NCT05279703
Drug: Epinephrin 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine infusion rate of 0.02 mcg/kg/min
Trial: NCT05279703
Drug: Epinephrin 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine infusion rate of 0.01 mcg/kg/min
Trial: NCT06289205
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
Trial: NCT06431971
Drug: Talineuren
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talineuren infusion weekly
Trial: NCT06431971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion weekly
Trial: NCT05021640
Drug: Placebo for DCR-AUD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline for injection
Trial: NCT06067191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04353661
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin will be administered orally.
Trial: NCT04911751
Drug: KBL697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule BID of KBL697 or Placebo
Trial: NCT06124001
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
Trial: NCT04911751
Drug: KBL697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 capsules BID of KBL697 or Placebo
Trial: NCT06504732
Drug: IAH0968
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
Trial: NCT05702827
Drug: Bupivacaine-Meloxicam
RxNorm normalized name: bupivacaine-meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.
Trial: NCT05140148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT05049083
Drug: New Process SHR2554 tablet、Former Process SHR2554 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
Trial: NCT05049083
Drug: Former Process SHR2554 tablet、New Process SHR2554 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
Trial: NCT06452654
Drug: Comirnaty Injectable Product
RxNorm normalized name: Comirnaty Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination
Trial: NCT05808634
Drug: BA3182
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
Trial: NCT05849480
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).
Trial: NCT05263869
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT05242146
Drug: GB5121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing GB5121
Trial: NCT06322056
Drug: Standard control of SBP and intensive control of LDL-C
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
Trial: NCT06322056
Drug: Standard control of SBP and standard control of LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
Trial: NCT05281328
Drug: CAM2029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection using a pre-filled pen
Trial: NCT05281328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection using a pre-filled pen
Trial: NCT05867589
Drug: 68Ga/18F-FAPI-04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
Trial: NCT06312813
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1ml propylene glycol
Trial: NCT04316910
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
Trial: NCT05203341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT00000973
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05722964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo，Intravenous injection
Trial: NCT05726318
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoaxole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
Trial: NCT05641246
Drug: (VOLTAREN®) Emulgel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
Trial: NCT05950646
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
Trial: NCT06332872
Drug: 4% dimenticone liquid gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical formulation (liquid gel) only 1 application
Trial: NCT04687514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
Trial: NCT06067425
Drug: SAR442501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection; Subcutaneous injection
Trial: NCT05900466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching tablets once daily in the morning for 8 weeks
Trial: NCT05391789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
Trial: NCT04381468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Trial: NCT06210360
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/m² on Day 1 of a 14 day cycle
Trial: NCT05761795
Drug: IVMED 85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop
Trial: NCT05761795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drop
Trial: NCT04184882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06031389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
Trial: NCT04985344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
Trial: NCT06647940
Drug: R-CHOP Protocol
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Trial: NCT05440851
Drug: Usual care without routine corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
Trial: NCT05440851
Drug: Usual care without extending corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
Trial: NCT05440851
Drug: 4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
Trial: NCT05731973
Drug: Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
Trial: NCT05702229
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
Trial: NCT05702229
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
Trial: NCT05702229
Drug: AZD7789
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
Trial: NCT05702229
Drug: AZD0901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an anti Claudin18.2 ADC; IV infusion
Trial: NCT05702229
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral take, Q3W
Trial: NCT05784363
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
Trial: NCT05784363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
Trial: NCT05860270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive placebo 2 capsules per day.
Trial: NCT05778591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo.
Trial: NCT04671472
Drug: NPC-09
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be administered by the oral route with the same manner
Trial: NCT04671472
Drug: NPC-09 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be administered by the oral route with the same manner
Trial: NCT06557473
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl IV 2 µg/kg for GA induction
Trial: NCT05226013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06224387
Drug: CTS2190 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
Trial: NCT06437431
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
Trial: NCT06385925
Drug: TSN1611
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Trial: NCT05570058
Drug: RXC007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
Trial: NCT04475198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Dextrose Injection
Trial: NCT05570058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
Trial: NCT01010724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05382767
Drug: CKDB-501A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle Spasticity
Trial: NCT05382767
Drug: Botox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle Spasticity
Trial: NCT04641338
Drug: Fixed dose combination Dipyrone and Codeine
RxNorm normalized name: dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
Trial: NCT04641338
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg codeine every 6 hours if necessary.
Trial: NCT04911075
Drug: 85% TCA Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes.
Trial: NCT06505772
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study.
Trial: NCT06294743
Drug: Acetaminophen 500Mg Tab
RxNorm normalized name: ACETAMINOPHEN 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
Trial: NCT05918198
Drug: Ven+CAG
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)
Trial: NCT05884866
Drug: Balcinrenone 50mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arms
Trial: NCT05884866
Drug: Balcinrenone 100mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arms
Trial: NCT05884866
Drug: Balcinrenone 50mg matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arms
Trial: NCT05884866
Drug: Balcinrenone 100mg matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arms
Trial: NCT05105035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be prescribed placebo every 12 hours for Days 1-14.
Trial: NCT05773053
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
Trial: NCT05773053
Drug: NT 201 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT 201 Matching-placebo.
Trial: NCT04718844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride for s.c. injection
Trial: NCT04752644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBS (Placebo) as intramuscular injections (0.5ml)
Trial: NCT04727580
Drug: HSK7653 10mg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
Trial: NCT04727580
Drug: HSK7653 25mg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Trial: NCT04727580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Trial: NCT05641623
Drug: OSU6162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSU6162
Trial: NCT05641623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05049902
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use according to the drug combination options selected by each center.
Trial: NCT05049902
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use according to the drug combination options selected by each center.
Trial: NCT05527288
Drug: Drug: [18F]florbetaben
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
Trial: NCT04422275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.